Could Graves Data Alter The Investment Case For Biohaven (BHVN)?
Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting
Biohaven Announces Progress Across Its Graves' Disease Program, Including Active Enrollment In Pivotal Phase 3 Trial Of BHV-1300 And Three Scientific Presentations At The American Thyroid Association Meeting; Phase 3 Trial Of BHV-1300 In Graves' Disease Is Enrolling At 55+ Active Sites In U.S. And Canada, With More Opening In UK, Japan, Australia And EU
Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $21
Biohaven Consensus Price Target Increased 10.16% to $24.48
Canaccord Genuity Maintains Buy on Biohaven, Raises Price Target to $32
Is Biohaven (BHVN) Undervalued After Its Narrower Loss And BHV 1420 Data?
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
Biohaven Q3 Adj. EPS $(0.73) Beats $(0.74) Estimate
Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to Trade
Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy
Biohaven Presents Preclinical Data For BHV-1420 At American Society Of Nephrology Kidney Week 2026
Biohaven Could Transform With Troriluzole's FDA Approval, RBC Says
Why Biohaven (BHVN) Is Up 25.0% And What's Next After FDA Review Acceptance
RBC Capital Maintains Sector Perform on Biohaven, Raises Price Target to $22
Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target Upgrade
Why Biohaven Catapulted 25% — And Why It Might Not Be Done Sprinting
Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again
Biohaven’s previously rejected rare disease drug to get fresh FDA review
BHVN Stock Eyes Biggest Single-Day Gain In 4 Years After FDA Approval For Vyglxia
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.